Agreements

Date: 2017-09-26

Type of information: Services contract

Compound: research cell banks (RCBs) from the Selexis SUREtechnology Platform™

Company: OSE Immunotherapeutics (France) Selexis (Switzerland)

Therapeutic area: Technology - Services

Type agreement: services contract

Action mechanism:

cell bank. Selexis’ proprietary SUREtechnology Platform facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the biologics development continuum, spanning discovery to commercialization.

Disease:

Details:

• On November 15, 2016, Selexis, a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, and OSE Immunotherapeutics announced the signing of two service agreements that provide OSE Immunotherapeutics with access to high performance research cell banks (RCBs) from the Selexis SUREtechnology Platform™. The agreements are designed to help OSE Immunotherapeutics advance two of its preclinical products based on immune activation and regulation.
Effi-DEM is a new-generation checkpoint inhibitor that blocks the Signal Regulatory Protein-alpha (SIRP-alpha) receptor expressed by myeloid suppressor cells (MDSC) and tumor-associated macrophages (TAM). MDSC and TAM play a key role in tumor growth. By specifically targeting the SIRP-alpha receptor, Effi-DEM transforms suppressive cells into effector anti-tumor cells.
Effi-7 is a humanized monoclonal antibody targeting the CD127 receptor (the alpha chain of the Interleukin 7 receptor (IL-7R)). It induces a powerful antagonist effect for better control of the pathogenic T lymphocytes involved in autoimmune diseases. The strategy of blocking the IL-7 has demonstrated efficacy in restoring the impaired immune balance in autoimmune diseases of the bowel in several preclinical models, such as ulcerative colitis.

Financial terms:

Latest news:

• On September 26, 2017, Selexis and OSE Immunotherapeutics announced the signing of two commercial license agreements (CLAs) that provide OSE with access to high-performance research cell banks (RCBs) developed using the Selexis SUREtechnology Platform™. The agreements are designed to support the advancement of the clinical development of OSE-172 (Effi-DEM), OSE’s new generation immune myeloid checkpoint inhibitor, as well as OSE-703 (Effi-3), OSE’s cancer immunotherapy, which is a cytotoxic monoclonal antibody targeting the IL-7 receptor. This is the third signed commercial license agreement with OSE Immunotherapeutics. OSE-172 (Effi-DEM) is a monoclonal antibody targeting SIRP-?, expressed on suppressive myeloid cells involved in the tumor microenvironment. As selective antagonist of SIRP-?, OSE-172 transforms the tumour microenvironment by blocking suppressor cells and activating anti-tumour effector cells. OSE-172 is planned to enter Phase 1/2 clinical phase in 2018. OSE-703 (Effi-3) is a humanized monoclonal antibody directed against the extracellular domain of the alpha-chain of the receptor for interleukin-7, cytotoxic for human cells expressing CD127. Under a research collaboration with Memorial Sloan Kettering Cancer Center, the cancer immunotherapy is in preclinical studies for solid tumors with non-small cell lung cancer (NSCLC) as the primary cancer model.